Nexalin Technology May Be the Future of Opiate Addiction Treatment

[junkie-button url=”” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

Nexalin Technology, subsidiary of Legacy Ventures International, Inc. is an FDA cleared medical device that utilizes a safe, non-invasive, non-drug treatment for anxiety, depression, and insomnia.

Nexalin states they have initiated pilot trials in addiction treatment centers around the United States for the treatment of opiate addiction. The pilot data indicates a significant reduction in cravings and withdrawal symptoms associated with early recovery. Additional clinical observations indicated that patients in early sobriety were able to sustain their commitment to abstinence from drugs and alcohol including opiates. This success has prompted the undertaking of formal clinical trials designed to investigate Nexalin Technology as an alternative opiate addiction treatment.

Currently, Nexalin Technology is engaged in clinical trials designed by the University of Pennsylvania to study the effect of Nexalin in patients with major depressive disorder (MDD). Additional clinical trials will be designed by the University of Pennsylvania, in collaboration with the University of Arizona, utilizing Nexalin as a form of treatment for patients with opiate addiction. These new clinical trials will take place at Carrier Clinic in New Jersey.

Randall Letcavage, Nexalin Technology’s President and CEO stated: “Our mission is to improve the lives of those suffering from substance abuse disorder and depression.” Letcavage further stated, “The Company supports President Trump’s declaration that the opiate epidemic is a national emergency. With opiate addiction at record levels, Nexalin Technology will allocate additional resources to investigate the Nexalin treatment as an adjunctive therapy for substance abuse disorder with specific focus on opiate addiction.”

Nexalin Technology was cleared by the FDA in 2003 as a safe and effective treatment for patients who suffer from anxiety, depression and insomnia. These are the same side effects associated with addiction that contribute to relapse. The Nexalin device emits a frequency-based waveform that interacts with structures of the mid-brain that regulate and stabilize the neurotransmitters associated with brain health. Nexalin consists of 15 to 20 treatments over a 3-4 week period. The treatment is comfortable and relaxing for all patients.

Mark White, Nexalin’s Chief Operating Officer, commented: “Science indicates that addiction is a brain based disease. At Nexalin, we believe the treatment of addiction will begin in the brain, especially when opiates are the drug of choice. Pilot data and clinical trial design validates the importance of Nexalin as a brain based addiction treatment.”